2. Search Result
Search Result
Results for "

oncogenic

" in MedChemExpress (MCE) Product Catalog:

101

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

1

Inhibitory Antibodies

9

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126979
    Mycro2

    		c-Myc Cancer
    Mycro2 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC50 value of 23 μM for the inhibition of Myc/Max DNA binding activity. Mycro2 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .
    Mycro2
  • HY-144256
    CHD1Li 6.11

    		DNA/RNA Synthesis Cancer
    CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties .
    CHD1Li 6.11
  • HY-120373
    MB710
    1 Publications Verification

    		 MDM-2/p53 Cancer
    MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines .
    MB710
  • HY-149241
    SHP2-IN-13

    		SHP2 Cancer
    SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.
    SHP2-IN-13
  • HY-117548
    UNC1062
    2 Publications Verification

    		 TAM Receptor Cancer
    UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC50=1.1 nM, Morrison Ki=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC50=60 nM, AXL IC50=85 nM) .
    UNC1062
  • HY-W048303
    L-Azatyrosine

    		Antibiotic Infection Cancer
    L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes .
    L-Azatyrosine
  • HY-125636
    Mycro1

    		c-Myc Cancer
    Mycro1 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC50 value of 30 μM for the inhibition of Myc/Max DNA binding activity. Mycro1 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .
    Mycro1
  • HY-143713
    Aurora A inhibitor 1

    		Aurora Kinase Cancer
    Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49) .
    Aurora A inhibitor 1
  • HY-151287
    KRAS inhibitor-20

    		Ras Cancer
    KRAS inhibitor-20 is a small molecular inhibitor of KRas G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas G12C with the IC50 value <10 nM .
    KRAS inhibitor-20
  • HY-150926
    G12Si-1

    		Ras Cancer
    G12Si-1 is a selective K-Ras(G12S) covalent inhibitor, which can inhibit oncogenic signaling of K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S) at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange .
    G12Si-1
  • HY-12408
    6H05

    		Ras Cancer
    6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
    6H05
  • HY-12408A
    6H05 TFA

    		Ras Cancer
    6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
    6H05 TFA
  • HY-164482
    HG-6-63-01

    		RET Cancer
    HG-6-63-01 is a type II RET tyrosine kinase inhibitor (TKI). HG-6-63-01 also inhibits REarranged during Transfection (RET) kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles. HG-6-63-01 impairs phosphorylation and signalling of RET oncogenic mutants. HG-6-63-01 blunts proliferation of RET/C634R and RET/M918T-transformed fibroblasts and of RET mutant thyroid cancer cells, which is promising for research of cancers harboring oncogenic activation of RET .
    HG-6-63-01
  • HY-106381A
    Aurothiomalate tetramer sodium

    		PKC Inflammation/Immunology
    Aurothiomalate tetramer sodium, an Aurothiomalate sodium (HY-106381) tetrameric form, is antiarthritic gold agent. Aurothiomalate sodium is a potent and selective oncogenic PKCι signaling inhibitor .
    Aurothiomalate tetramer sodium
  • HY-147361
    LDCA

    		Apoptosis Lactate Dehydrogenase Cancer
    LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .
    LDCA
  • HY-14754
    Salirasib
    Maximum Cited Publications
    10 Publications Verification

    S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS

    		 Ras Autophagy Cancer
    Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib
  • HY-P10488
    cycFWRPW

    		Wnt Others Cancer
    cycFWRPW is a peptide inhibitor of TLE1. TLE1 is an oncogenic transcriptional co‐repressor that exerts its repressive effects through binding of transcription factors, and inhibits Wnt signaling .
    cycFWRPW
  • HY-120885
    (+)-Oxanthromicin

    		Ras Cancer
    (+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .
    (+)-Oxanthromicin
  • HY-162350
    TDI-11055

    		Endogenous Metabolite Cancer
    TDI-11055 is an inhibitor of the epigenetic reader protein 11-19 leukemia (ENL) YEATS, which drives the oncogenic transcriptional program of acute myeloid leukemia (AML), the hematopoietic malignancy AML .
    TDI-11055
  • HY-162752
    Anticancer agent 250

    		Apoptosis Cancer
    Anticancer agent 250 (compound 104) has antitumor activity, inducing apoptosis, slowing proliferation, and degrading key oncogenic proteins (such as aRaf, CDK4 ) without inducing a heat shock response .
    Anticancer agent 250
  • HY-176269
    VS1150

    		Bcr-Abl ERK STAT PARP Caspase Apoptosis Cancer
    VS1150 (Compound 11) is a BCR-ABL-targeting phosphorylation-inducing chimeric small molecule (PHICS). VS1150 significantly inhibits oncogenic kinase BCR-ABL signaling by inducing inhibitory phosphorylation at its Y253 (EC50: 69 nM), subsequently triggering cell apoptosis. VS1150 also inhibits other oncogenic ABL fusions and drug-resistant mutants like T315I. VS1150 can be used for chronic myeloid leukemia (CML) and other ABL fusion-driven cancers research .
    VS1150
  • HY-108508
    SMANT hydrochloride

    		Smo Hedgehog Cancer
    SMANT hydrochloride is a Smoothened (Smo) signaling inhibitor. SMANT hydrochloride is antagonist of Smo accumulation within the primary cilium (PC). SMANT hydrochloride has an equivalent activity in inhibiting SmoM2 (oncogenic form of Smo) and wild-type Smo .
    SMANT hydrochloride
  • HY-15872A
    FTI-277 hydrochloride
    5 Publications Verification

    		 Farnesyl Transferase Apoptosis Ras Infection Cancer
    FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 hydrochloride can inhibit hepatitis delta virus (HDV) infection.
    FTI-277 hydrochloride
  • HY-15872
    FTI-277

    		Farnesyl Transferase Apoptosis Ras Infection Cancer
    FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 can inhibit hepatitis delta virus (HDV) infection.
    FTI-277
  • HY-14754R
    Salirasib (Standard)

    S-Farnesylthiosalicylic acid (Standard); Farnesyl Thiosalicylic Acid (Standard); FTS (Standard)

    		 Reference Standards Ras Autophagy Cancer
    Salirasib (Standard) is the analytical standard of Salirasib. This product is intended for research and analytical applications. Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib (Standard)
  • HY-N11794
    7-Ketologanin

    		Others Others
    7-Ketologanin is an iridoid glucoside. 7-Ketologanin can be isolated from the Stems of Viburnum erosum. 7-Ketologanin involves in biosynthetic pathway of oleuropein. Oleuropein, is a bioactive phenolic compound, modulates several oncogenic signalling pathways .
    7-Ketologanin
  • HY-139402
    MRTX849 acid

    		Ras Cancer
    MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM) .
    MRTX849 acid
  • HY-108436
    Deltazinone 1

    		Phosphodiesterase (PDE) Cancer
    Deltazinone 1, a pyrazolopyridazinone, is a highly selective PDEδ inhibitor with a KD of 8 nM. Deltazinone 1 inhibits the PDEδ-Ras interaction. Deltazinone 1 shows a dose-dependent inhibitory response on proliferation in oncogenic KRas-dependent cell lines .
    Deltazinone 1
  • HY-106381
    Aurothiomalate sodium

    		PKC Inflammation/Immunology Cancer
    Aurothiomalate sodium is a potent and selective oncogenic PKCι signaling inhibitor. Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium, an anti-rheumatoid agent, exhibits potent anti-tumor activity .
    Aurothiomalate sodium
  • HY-164548
    WK88-1

    		HSP Apoptosis Cancer
    WK88-1, a Hsp90 inhibitor, induces overall degradation of multiple oncogenic signaling molecules including EGFR, ErbB2 and ErbB3, leading to subsequent growth arrest and apoptosis in the Gefitinib-resistant H1975 cell line .
    WK88-1
  • HY-110038
    FTI-277 TFA

    		Farnesyl Transferase Apoptosis Ras Infection Cancer
    FTI-277 TFA is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 TFA can inhibit hepatitis delta virus (HDV) infection.
    FTI-277 TFA
  • HY-162126
    Tubulin polymerization-IN-58

    		Microtubule/Tubulin YAP Cancer
    Tubulin polymerization-IN-58 (Compound K18) is a tubulin polymerization inhibitor with an IC50 of 0.446 μM. Tubulin polymerization-IN-58 also induces the degradation of oncogenic protein YAP via the UPS pathway, thus can be used for cancer research .
    Tubulin polymerization-IN-58
  • HY-153534
    microRNA-21-IN-3

    		MicroRNA Cancer
    microRNA-21-IN-3 (compound 45) can specifically bind to the precursor of oncogenic and pro-inflammatory microRNA-21 with medium nanomolar affinity, reduce cancer cell proliferation and miR-21 levels, and can be used in antitumor research .
    microRNA-21-IN-3
  • HY-134582
    dCBP-1
    3 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .
    dCBP-1
  • HY-164488
    KT D606

    		PAK Cancer
    KT D606 is an inhibitor of the PAK kinase family, with an IC50 value of 4 μM. KT D606 selectively blocks the proliferation of cancer cells transformed by oncogenic RAS mutants and can be used for research on RAS/PAK1-induced cancers .
    KT D606
  • HY-135815
    Mobocertinib
    5+ Cited Publications

    TAK-788; AP32788

    		 EGFR Cancer
    Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .
    Mobocertinib
  • HY-135815B
    Mobocertinib mesylate

    TAK-788 mesylate; AP32788 mesylate

    		 EGFR Cancer
    Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research .
    Mobocertinib mesylate
  • HY-13007A
    PF-3758309 hydrochloride

    PF-03758309 hydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 hydrochloride
  • HY-13007
    PF-3758309
    Maximum Cited Publications
    10 Publications Verification

    PF-03758309

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309
  • HY-13007B
    PF-3758309 dihydrochloride

    PF-03758309 dihydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 dihydrochloride
  • HY-135815A
    Mobocertinib succinate
    5+ Cited Publications

    TAK-788 succinate; AP32788 succinate

    		 EGFR Cancer
    Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .
    Mobocertinib succinate
  • HY-P10652
    hsBCL9CT-24

    		Wnt β-catenin Cancer
    hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
    hsBCL9CT-24
  • HY-119607
    DYRKi

    		DYRK Cancer
    DYRKi is an inhibitor of DYRK1 and DYRK1B with IC50 values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers .
    DYRKi
  • HY-120909
    YK5

    		HSP Apoptosis Cancer
    YK5 is a potent and selective Hsp70 inhibitor. YK5 selectively and tightly binds to the cytosolic Hsp70s in cancer cells. YK5 has biological activity partly by interfering with the formation of active oncogenic Hsp70/Hsp90/client protein complexes .
    YK5
  • HY-139065
    AMPC

    		Others Cancer
    AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .
    AMPC
  • HY-124844
    Azaphilone-9

    AZA-9

    		 HuR Cancer
    Azaphilone-9 (AZA-9) is an inhibitor of HuR-ARE RNA interaction (IC50=1.2 μM) by binding RNA-binding protein Hu antigen R (HuR). The HuR-RNA interactions stabilize many oncogenic mRNAs in tumors. Thus Azaphilone-9 potentially inhibit cancer cell growth and progression .
    Azaphilone-9
  • HY-144096
    EZH2-IN-11

    		Histone Methyltransferase Cancer
    EZH2-IN-11 is a potent inhibitor of E2HZ. The oncogenic activities of EZH2 have been shown by a number of studies in various different cancer types. EZH2-IN-11 has the potential for the research of cancer diseases (extracted from patent WO2019204490A1, compound 17) .
    EZH2-IN-11
  • HY-122664
    XMU-MP-2

    		BRK Cancer
    XMU-MP-2 is a BRK inhibitor with significant inhibitory activity on BRK-positive cells. XMU-MP-2 inhibits oncogenic BRK-driven tumor growth in a mouse xenograft model. XMU-MP-2 also synergizes with HER2 inhibitors or endoplasmic reticulum (ER) blockade to exert antiproliferative activity .
    XMU-MP-2
  • HY-122866
    ZT-12-037-01

    		Ras Cancer
    ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM .
    ZT-12-037-01
  • HY-162250
    MS8847

    		PROTACs Histone Methyltransferase Cancer
    MS8847 is a highly potent EZH2 PROTAC degrader that recruits the E3 ligase von Hippel-Lindau (VHL). MS8847 potently degrades EZH2 in a ubiquitin-proteasome system-dependent manner. MS8847 effectively inhibits the growth of acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC) cells .
    MS8847

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: